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ABSTRACT:  
CpG motif is described as a type of Immunostimulatory Sequence (ISS)，
in which an unmethylated cytosine-phosphate-guanosine (CpG) motif is 
flanked by two 5′ purines and two 3′ pyrimidines. Since its discovery in 
1995, several studies have shown that ODNs containing unmethylated 
CpG motifs (designated as CpG ODN) can activate host immune defense 
mechanisms, leading to both innate and acquired immune responses 
through toll-like receptor 9 (TLR9)–mediated recognition.  
Synthetic CpG ODNs trigger an immunomodulatory cascade that involves 
professional antigen presenting cells, natural killer cells, B cells, and T 
cells, thereby underscoring their potential for use as immunoprotective 
agents as well as vaccine adjuvants. To date, the CpG ODNs used in most 
of the research were synthesized with a nuclease-resistant 
phosphorothioate backbone, while research on the adjuvanticity of 
plasmids containing multiple CpG motifs has rarely been reported. 
In our study, a swine-specific CpG motif enriched plasmid (pUC18-CpG) 
was constructed. The immunostimulant property of pUC18-CpG was 
tested in vitro via lymphocyte transformation assay using swine 
peripheral blood mononuclear cells (PBMCs). Our results showed that 
the recombinant plasmid showed higher Stimulation Index (SI) compared 
to the positive control lipopolysaccharides (LPS).  
Then pUC18-CpG as an adjuvant of FMD killed vaccine was tested for 
immunization and vaccination─challenge in a porcine model. Our 
results showed that co-administration of pUC18-CpG with the traditional 
FMD killed vaccine could significantly enhance the humoral immune 
response and generate higher levels of antibodies against FMDV 
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structural proteins. In addition, the PD50 value of the CpG adjuvanted 
vaccine was much higher than that of the traditional FMD killed vaccine. 
The efficacy enhancement property of pUC18-CpG was further 
investigated on a PRRS MLV vaccine. After vaccination, PRRSV-specific 
antibodies, PRRSV-specific cytokines and clinical parameters were 
studied and compared between different vaccinated groups. During the 
following challenge study, co-administration of pUC18-CpG with the 
vaccine could confer higher protection rate. Our results have shown that 
co-administration of pUC18-CpG with the vaccine could elicit more 
potent adaptive immune response and provide better protection. 
In summary, our research showed that pUC18-CpG could be a potent 
immunoadjuvant for the two swine vaccines and could greatly enhance 
the efficacy when administered in combination with either of them. 
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Resumen:  
1. Introducción 
La secuencia citosina-fosfato-guanosina (CpG) fue descrita como un tipo 
de inmunoestimulante de la respuesta inmune tanto humoral como 
celular. La secuencia CpG está flanqueada por dos purinas en 5’ y dos 
pirimidinas en el extremo 3’ (CpG—ODN). Desde su descubrimiento en 
1995, varios estudios han demostrado que ODN, que contiene la 
secuencia no metilada de CpG (señalada como CpG ODN), puede activar 
mecanismos de defensa inmune, y estimular la respuesta inmune tanto 
innata como adquirida. 
La secuencia CpG—ODN es reconocida por el receptor Toll–like 9 
presente en ciertos tipos de células del sistema inmune de los mamíferos. 
CpG-ODN es capaz de estimular el sistema inmune, siendo específico 
para las distintas especies animales. Los CpG ODNs provocan una cascada 
de inmunomodulador que involucra a las células presentadoras de 
antígenos profesionales, las células NK, las células B y células T, 
subrayando así su potencial de uso como inmunoestimulante, así como 
adyuvantes de las vacunas.  
La secuencia óptima para la estimulación de las células mononucleares 
de sangre periférica (PBMC) de cerdos fue descrita como GTCGTT . Hasta 
la fecha, la secuencia CpG-ODN con un fosforotionato resistente a la 
nucleasa ha sido empleada en la mayoría de los estudios previos. Sin 
embargo, pocos estudios han evaluado el funcionamiento, como 
adyuvante en cerdos, del plásmido que contiene la secuencia CpG. 
La fiebre aftosa (FA) es una de las enfermedades de notificación 
obligatoria a la OIE, y de las más importantes que afectan a diferentes 
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especies ganaderas. La vacunación es considerada como una estrategia 
muy importante para el control y erradicación de la enfermedad en áreas 
endémicas, así como en casos de brotes en áreas normalmente libres de 
la enfermedad. Sin embargo, en algunos casos la vacunación no ha 
logrado evitar la difusión y transmisión de la enfermedad, en parte 
debido al fracaso a la hora de originar una respuesta inmune eficaz tras 
la vacuna empleada. Por lo tanto, el diseño de nuevas vacunas contra la 
fiebre aftosa debería incluir el uso de un adyuvante más eficaz. 
Por otra parte, el síndrome reproductivo y respiratorio porcino (PRRS) se 
ha extendido en todo el mundo y sigue causando grandes pérdidas 
económicas en la industria porcina cada año. Las vacunas actuales contra 
la enfermedad están basadas en vacunas inactivadas y vacunas vivas 
atenuadas, realizadas con diferentes cepas de virus. Hasta la fecha, las 
vacunas vivas atenuadas han demostrado mejor eficacia de protección, 
especialmente contra la infección homóloga, pero su eficacia contra la 
infección heteróloga es variable. La utilización de adyuvantes inmunes 
más eficaces podría mejorar las vacunas vivas atenuadas. 
2. Objetivos 
Este trabajo tiene como principal objetivo la utilización de la secuencia 
CpG como inmunoestimulador en vacunas frente a la fiebre aftosa (FA) y 
el síndrome reproductivo y respiratorio porcino (PRRS), incluyendo: 
(1) Construcción del plásmido que contiene la secuencia de CpG 
específica de cerdos y el estudio de sus efectos inmunoestimulantes 
in vitro; 
(2) Evaluación del efecto inmune del plásmido que contiene el CpG, 
como adyuvante de una vacuna viva atenuada contra el síndrome 
RESUMEN 
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reproductivo y respiratorio porcino; 
(3) Evaluación del efecto inmune del plásmido que contiene el CpG 
como adyuvante en una vacuna inactivada frente al virus de la fiebre 
aftosa. 
3. Resultados 
El plásmido que contiene las secuencias CpG específicas para cerdos 
(pUC18-CpG) se logró a través de la inserción en tándem de 5 copias de 
CpG ODN 2006 en los múltiples sitios de clonación del vector del 
plásmido pUC18. La propiedad inmunoestimulante de pUC18-CpG fue 
probada in vitro mediante el ensayo de la transformación de linfocitos, 
utilizando células mononucleares de sangre periférica de cerdos. 
Nuestros resultados mostraron que el plásmido recombinante mostró 
mayor índice de estimulación (SI) en comparación con el control de 
lipopolisacáridos (LPS). 
En el estudio siguiente, el pUC18-CpG fue probado como coadyuvante en 
una vacuna inactivada frente al virus de la fiebre aftosa, en un modelo 
porcino con inmunización, vacunación y desafío. Nuestros resultados 
mostraron que la co-administración del pUC18-CpG con la vacuna 
inactivada de FA podría mejorar significativamente la respuesta 
inmunitaria humoral y generar mayores niveles de anticuerpos (más de 
1,5 veces) contra las proteínas estructurales del VFA. Durante la prueba 
de potencia, se mostró que la co-administración de pUC18-CpG con la 
vacuna inactivada de FA mejoró la potencia de esta última (PD50 values: 
12.51, 6.47).  
Por otra parte, el pUC18-CpG también se probó en una vacuna viva 
atenuada contra el síndrome reproductivo y respiratorio porcino. 
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Después de la vacunación, diferentes parámetros fueron evaluados: 
anticuerpos, citoquinas específicas para PRRS, y parámetros clínicos, 
comparándo los grupos vacunados con los controles. La 
co-administración de pUC18-CpG con la vacuna PRRS ayudó a inducir una 
respuesta inmune humoral más elevada, y dio lugar a un tipo de 
respuesta inmune Th1. Durante el siguiente estudio de desafío, la 
co-administración del pUC18-CpG con la vacuna viva atenuada del PRRS 
redujo las síntomas clínicos e incrementó la tasa en protección 
(protección completa en el Grupo B con el pUC18-CpG). 
4. Conclusión 
Nuestra investigación ha demostrado que pUC18-CpG puede actuar 
como un potente inmunoadyuvante para las dos vacunas porcinas 
utilizadas en este estudio y mejorar la eficacia de ambas cuando se 
administra en combinación con ellas. 
INTRODUCTION 
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1.1 CpG ODN: discovery, mechanisms and therapeutic applications    
1.1.1 Innate immunity, PAMPs and PRRs 
The immune system of vertebrates comprises two branches: the innate 
immunity and the adaptive immunity. The innate immune system is the 
first line in defending against the invasion of pathogenic microorganisms 
(Akira, Uematsu, and Takeuchi, 2006). The exposure of pathogens first 
triggers the innate immune response that is characterized by the 
production of type I interferons and other inflammatory cytokines 
(Medzhitov and Janeway, 1997). Subsequently, the adaptive immune 
response is triggered to eliminate pathogens in the late phase of 
infection as well as to generate immunological memory. 
The innate immune system recognizes pathogen-associated molecular 
patterns (PAMPs) expressed by the infectious microorganisms (Janeway, 
1989). PAMPs are conserved microbial structures such as LPS, flagellin or 
bacterial CpG DNA, etc. Recognition of PAMPs is mediated by the 
germline-encoded pattern-recognition receptors (PRRs) (Janeway and 
Medzhitov, 2002). So far, the PRRs are broadly categorized into 3 classes: 
secreted PRRs, transmembrane PRRs and cytosolic PRRs (Iwasaki and 
Medzhitov, 2010). 
Toll-like receptors are members of the transmembrane PRRs family, and 
are among the most studied PRRs. Up to now, 12 members of the TLR 
family have been identified in mammals (Kumar, Kawai, and Akira, 
2009b). Among them, TLR1, TLR2, TLR4, TLR5 and TLR6 are located on 
the cell surface, and detect PAMPs such as lipopolysaccharide (LPS) of 
Gram-negative bacteria (TLR4), lipoteichoic acids of Gram-positive 
bacteria (TLR1/TLR2), bacterial lipoproteins (TLR2/TLR6) and flagellin 
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(TLR5) (Hayashi et al., 2001; Ozinsky et al., 2000; Poltorak et al., 1998). 
TLR3, TLR7 and TLR9 are located on intracellular vesicles, and recognize 
double-stranded RNA (dsRNA) (TLR3), single-stranded RNA (ssRNA) 
(TLR7), and dsDNA (TLR9) (Alexopoulou et al., 2001; Diebold et al., 2004; 
Hemmi et al., 2000). 
1.1.2 The discovery of CpG ODN  
In the genomes of vertebrates, CpG dinucleotides exist at lower 
frequency, only about one-quarter of the prevalence exist in bacterial 
DNA, and are often highly methylated when appear (Bird et al., 1987; 
Yamamoto et al., 1992). During the early stage of antisense ODN 
research, unexpected stimulation of lymphocyte proliferation and 
immunoglobulin production were reported (Branda et al., 1993; 
McIntyre et al., 1993; Tanaka, Chu, and Paul, 1992). In 1995, Krieg and 
his colleagues reported that it was the CpG motif existed in the antisense 
ODNs that is responsible for the immune stimulation (Krieg et al., 1995). 
A CpG motif is described as an ODN in which the CpG dinucleotides are 
flanked by two 5’ purines and two 3’ pyrimidines. The 
immunostimulatory properties of the CpG ODN are affected by the 
number of CpG motifs it contains, the space between the CpG motifs, 
additional flanking sequences and the ODN backbone (Hartmann and 
Krieg, 2000; Hartmann et al., 2000; Wloch et al., 1998). And the immune 
stimulatory effects of the CpG ODN could be further enhanced if the 
ODN contains a TpC dinucleotide on the 5’ end and is pyrimidine rich on 
the 3’ side (Hartmann et al., 2000). 
Due to the divergence in the molecular structure of TLR9 in different 
species throughout evolution, the optimal CpG ODN sequence for 
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stimulating immune cells may differ among species (Rankin et al., 2001). 
For example, the TLR9 molecules of mice and human differ by 24% at the 
amino-acid level (Hemmi et al., 2000). Hence the optimal CpG ODN 
sequence for activating mouse immune cells is GACGTT, while the 
optimal sequence for activating human immune cells is GTCGTT (Krieg, 
Hartmann, and Yi, 2000; Rankin et al., 2001). 
Cell populations that could express TLR9 may also differ among species. 
In mice, the immune cells of monocytes, macrophages and myeloid DCs 
could express TLR9 and respond to CpG stimulation, whereas in human, 
it is the B cells and pDCs that express TLR9 and mediate CpG activation 
(Hartmann and Krieg, 2000; Krug et al., 2001). 
1.1.3 Mechanisms for immunostimulation by CpG ODN  
It is reported that members of the phosphoinositide (PI) 3-kinase family 
play an important role in the uptake of CpG ODN by immune cells (Ishii 
et al., 2002). After internalization, CpG ODN is shuffled to and interacts 
with TLR9 that is present on endosomes. Interaction of TLR9 with CpG 
ODN triggers the swelling and acidification of the endosomes and the 
release of reactive oxygen species (ROS), which is very crucial to the 
following steps of the TLR9-mediated immunostimulation signaling 
pathway (Hacker et al., 1998; Yi et al., 1998). 
The TLR9-mediated cellular activation involves a signaling cascade that is 
MyD88-dependent. In macrophages and conventional dendritic cells 
(cDCs), the signal transduction proceeds via the recruitment and 
activation of the IRAK family proteins, TRAF6, TAK1 and the IKK complex. 
The activation of the IKK complex activates the NF-κB subunits to initiate 
the transcription of inflammatory cytokine genes (Kawai and Akira, 2010; 
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Lin, Lo, and Wu, 2010; Tseng et al., 2010).  
In pDCs stimulated with CpG ODN, the MyD88-mediated signaling 
pathway involves proteins such as IRAK4, TRAF6, TRAF3, IRAK1, and IKKa, 
which in turn phosphorylate IRF7 to initiate the transcription of type I 
interferons. In addition, proteins such as osteopontin, phosphoinositol 3 
kinase (PI3K), mTOR (downstream of PI3K) and p70S6K also play critical 
roles in IRF7 activation (Kumar, Kawai, and Akira, 2009a; Takeuchi and 
Akira, 2010). 
All the above-mentioned immunostimulatory effects are highly CpG 
specific, since ODN lacking the corresponding CpG motifs does not 
stimulate the secretion of proinflammatory cytokines and type I 
interferons (Gursel et al., 2002; Klinman et al., 1996). 
1.1.4 Immunotherapeutic applications of CpG ODN 
Immunoprotection and therapy. During evolution, the innate immune 
system of vertebrates could recognize and respond to the PAMPs of 
infectious pathogens, indicating that PAMP-mediated immune activation 
may be vital for host survival. In fact, the treatment of mice with a 
species-specific CpG ODN did provide immune protection against 
intracellular infectious challenges. CpG-treated mice could resist a wide 
range of infection by bacteria and viruses, and even by parasites (Ashkar 
et al., 2003; Klinman, Conover, and Coban, 1999; Ray and Krieg, 2003). 
Post-exposure therapy with CpG ODN is generally less effective against 
acute viral infections compared to the effectiveness against chronic viral 
infections, suggesting its potential utility in the treatment of the latter. 
TLR9 activation leads to the inhibition of replication of hepatitis B virus in 
vivo, and improves the survival in a Friend leukaemia virus model when 
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given four days post-infection (Isogawa et al., 2005; Olbrich et al., 2002). 
Moreover, it has been reported that the administration of CpG ODNs 
could improve the protection of the immunosuppressed, the pregnant 
and the newborn against infection (Ito et al., 2004; Verthelyi et al., 
2003). 
Vaccine adjuvants. CpG ODN stimulates the expression of inflammatory 
cytokines and type I interferons, and activates professional APCs, 
suggesting that CpG ODNs may be utilized as vaccine adjuvants. Up to 
2011, over 600 preclinical studies have been carried out in examining the 
immunogenicity of CpG-adjuvanted vaccines (Bode et al., 2011). 
Co-administration of vaccines with CpG ODN could enhance 
antigen-specific humoral and cellular responses to the antigens, 
including subunit vaccines, killed or live attenuated vaccines, dendritic 
cell vaccines, etc.  
In order to achieve the optimal antigen-specific immune response, it is 
necessary that the CpG ODN be maintained in close proximity to the 
antigen. Thus, conjugation of CpG ODN to the antigen by physical or 
chemical methods, or incorporating them in lipid emulsions or vesicles, 
could greatly enhance the specific IgG responses (Davis et al., 1998; 
Gursel et al., 2001). The mechanisms responsible for the strong adjuvant 
effects may include: 1) CpG-induced activation and maturation of APCs; 2) 
inhibition of B cell apoptosis; and 3) CpG-induced Th1-biased cytokine 
microenvironment. Meanwhile, conjugation of CpG ODN with the 
antigen can improve antigen uptake and thus reduce antigen dose (Tighe 
et al., 2000; Weeratna, Comanita, and Davis, 2003). 
The ability of CpG ODN in boosting mucosal immunity has also been 
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evaluated. Multiple studies have proved that CpG ODN is an effective 
mucosal adjuvant for the respiratory tract, vaginal mucosal, oral, 
intrarectal and conjunctival vaccination, as well as transcutaneous 
immunization (Berry et al., 2004; McCluskie and Davis, 2000; Nesburn et 
al., 2005). CpG-adjuvanted vaccination through mucosal routes 
presented enhanced protection against infectious challenge. 
In human clinical trials, CpG ODN has been studied as adjuvant for 
hepatitis B surface antigen, alone or in combination with alum. During a 
randomized double-blind controlled trial in HIV-infected populations, 
addition of CpG ODN to the Engerix-B vaccine significantly enhanced 
both the anti-HBs antibody titers and the antigen-specific T cell 
proliferative responses (Cooper et al., 2005; Cooper et al., 2004). 
Moreover, the ability of CpG ODN to induce a Th1-biased immune 
response and support CD8+ T-cell responses suggests its potential use as 
adjuvant for allergy vaccines and cancer vaccines. 
Treatment of cancer and allergic diseases. By activating the innate 
immune system and inducing IFN-gamma production, CpG ODN 
manifests antitumor activity in mouse models and human preclinical 
trials. In mice, CpG ODN-mediated immune activation could result in 
tumor eradication, but this therapy only applies to relatively small 
tumors. For the treatment of large tumors, CpG ODN has shown better 
results when administered in combinations with other types of 
anti-tumor therapies, like monoclonal anti-tumor antibodies, surgery, 
radiotherapy and chemotherapy (Krieg, 2004). 
In human, CpG ODN has shown promising results in cancer 
immunotherapy. Several pharmaceutical companies, including Pfizer, 
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Idera and Dynavax, are developing CpG ODNs for the treatment of cancer. 
CpG ODN monotherapy has entered clinical trials for the treatment of 
non-Hodgkin lymphoma (NHL), renal cell carcinoma, melanoma, and 
non-small cell lung cancer. And several TLR9 agonists have been 
developed and have entered clinical trials to evaluate their safety and 
efficacy for the treatment of several hematopoietic and solid tumors 
(Murad and Clay, 2009).  
Asthma is an allergic disease of the respiratory systems, which is resulted 
from over Th2-type immune response against the harmless antigens in 
the environment. The disease is mediated by the over-production of 
Th2-type cytokines like IL-4 and IL-5, and the increased differentiation of 
B cells into IgE secreting cells (Robinson et al., 1992). CpG ODN 
stimulates Th1-type immune response and elicits the production of IFN-γ 
and IL-12, which in turn suppress the Th2-type immunity and IL-4 
production. Hence, by administration of CpG ODN, the allergic asthma 
may be reduced or eliminated. In fact, the anti-allergic properties of CpG 
ODN were reported when it was administered alone, mixed with allergen 
or physically linked to allergen (Horner et al., 2002). 
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1.2 Foot-and-mouth Disease                                 
1.2.1 Etiology and current situation 
Foot-and-mouth disease (FMD) is one of the notifiable diseases listed by 
the OIE. The causative agent of FMD is the foot-and-mouth disease virus 
(FMDV), a member of the Genus Aphthovirus in the Family 
Picornaviridae. There are seven serotypes of FMDV—A, O, C, SAT1, SAT2, 
SAT3 and Asia1, with each serotype containing several subtypes (Doel, 
2003; Sumption, Rweyemamu, and Wint, 2008). During an outbreak, 
FMD causes high morbidity, with low to moderate mortality. Typical 
infection by FMDV is characterized by a vesicular condition of the feet, 
buccal mucosa and, in females, the mammary glands. 
Different serotypes of FMDV are currently existed in different regions 
and countries, with the potential of rapid international spread (Zhang et 
al., 2011). Being one of the most contagious animal diseases, FMD 
affects millions of cloven-footed animals worldwide annually, causes 
severe economic losses and remains the main sanitary barrier in the 
international and national trade of animals and animal products. 
Therefore, it is of great importance to develop efficient strategies for the 
prevention, control and eradication of FMD. 
1.2.2 Recent progress in FMD vaccine development 
Vaccination has been proven to be a powerful strategy for control and 
eradication of animal infectious diseases. The first inactivated FMD 
vaccine was developed in the 1930’s, through the inactivation of 
vesicular fluid obtained from deliberately infected cattle. For the present, 
FMD killed vaccine is produced by growing the live virulent strains of 
FMDV in BHK-21 cell lines under bio-secure conditions, inactivation by 
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chemicals such as binary ethyleneimine, and then formulated with 
oil-adjuvants (Doel, 2003; Lombard, Pastoret, and Moulin, 2007).  
However, the manufacturing process of FMD killed vaccine may risk the 
release of the live virus to the environment because of incomplete 
inactivation, causing biosafety issues. Also, FMD killed vaccine exhibits 
other disadvantages such as the need of adequate cold chain of 
formulated vaccines , necessity of multiple vaccinations, short shelf life, 
etc., which calls for a better FMD vaccine design strategy. 
During the past decades, several novel FMD vaccines have been 
developed in the lab and tested through animal experiments, and show 
very promising results. Among them there are: 
Synthetic peptide vaccines are designed to include both T and B cell 
antigenic epitopes optimized for both immunogenicity and antigenicity. 
The synthesized peptide spans the variable G–H loop region, the 
carboxy-terminal part of VP1 and regions that represents FMDV T-cell 
epitopes (Wang et al., 2002). The efficacy of peptide vaccines is 
restricted by representing only a limited number of antigenic sites and/or 
T-cell epitopes of the virus. Rational designs of advanced structure of 
antigen peptide may provide more powerful FMD peptide vaccines. 
Empty capsid vaccines are virus-like particles (VLPs) lacking the nucleic 
acid. The earliest VLPs were naturally produced in infected cells and were 
as immunogenic as virions (Rweyemamu, Terry, and Pay, 1979). Currently 
a number of expression systems have been utilized for the production of 
VLPs, including virus vectors, prokaryotic expression system and the 
baculovirus expression system. The delivery of the FMDV capsid 
sequence via a recombinant, replication-defective human adenovirus 
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type 5 (Ad5) provided early protection against challenge during a clinical 
study (Pacheco et al., 2005). And FMDV VLPs obtained through the 
silkworm-baculovirus expression system also showed good 
immunogenicity (Li et al., 2008). 
Live attenuated vaccines are nowadays engineered with the infectious 
cDNA technologies, which allow the introduction of specific changes in 
the FMDV genome. A genetically engineered FMDV serotype A12 lacking 
a leader proteinase was attenuated and was not transmissible between 
cattle or swine, while induced protective immune response 
(Chinsangaram, Mason, and Grubman, 1998; Piccone et al., 1995). The 
discovery of more virulence determinants will contribute to the 
development of new types of attenuated vaccines, with the background 
of a better understanding of the virus-host interactions and mechanisms 
of virus pathogenesis.  
DNA vaccines have several advantages over traditional vaccines, such as 
long-term protection, long shelf life and the ability to induce both 
humoral and cellular immune responses (Fowler and Barnett, 2012). 
Plasmids encoding antigenic epitopes of FMDV structural protein VP1 
could elicit immune responses in mice and protected swine against viral 
infection (Wong et al., 2000). Moreover, several cytokines have proven to 
be efficient immunoadjuvants of DNA vaccines, including INF-gamma, 
IL-2, IL-6, etc. 
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1.3 Porcine Reproductive and Respiratory Syndrome: current 
situation and challenges in vaccinology 
1.3.1 Etiology and current situation 
Porcine reproductive and respiratory syndrome (PRRS) is a swine disease 
that first emerged in the United States during the 1980s (Madsen et al., 
1998). The causative agent of the disease is the PRRS virus (PRRSV), 
which is a small, enveloped virus belonging to the family Arteriviridae, 
genus Arterivirus. PRRSV is believed to replicate in macrophages, and 
adopt several mechanisms to evade the host’s immune surveillance (Yoo 
et al., 2010). 
PRRSV is an enveloped, single-stranded, positive sense RNA virus. The 
genome of PRRSV is about 15.4kb, which encodes for at least 10 open 
reading frames (ORFs) (Dokland, 2010). Based on nucleotide sequence 
analysis and comparison, PRRSV is categorized into type 1 and type 2 
genotypes, representing the European and North American isolates, 
respectively. There is about 70% of homology at the nucleotide level 
between the two genotypes (Nelsen, Murtaugh, and Faaberg, 1999; 
Wootton, Yoo, and Rogan, 2000). 
Due to the high error-rate inherent in PRRSV replication and 
recombination between different strains, there is an increasing diversity 
among strains of the two genotypes (Chang et al., 2002; van Vugt et al., 
2001). Investigations have shown regional differences within each 
genotype. There have been reports on the high degree of polymorphism 
of the type 1 PRRSV in east Europe (Stadejek et al., 2006). Nowadays, 
type 2 PRRSV has been introduced into Europe and type 1 virus has 
appeared in North America, which may accelerate the evolution and 
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polymorphism of the virus. 
Most isolates of PRRSV discovered in South America and Asia belong to 
the type 2 genotype, probably due to the movement of swine and/or 
semen. In China, a highly virulent strain of type 2 PRRSV appeared in 
2006, characterized by a discontinuous 30 amino acids deletion in the 
NSP2 region (Tong et al., 2007). 
1.3.2 Recent progress in PRRSV vaccine development 
Inactivated PRRSV vaccines have been developed and usually 
administered in combination with immunoadjuvants, with the purpose 
of eliciting specific anti-PRRSV humoral responses. In fact, killed PRRSV 
vaccines are the only permitted vaccines in UK and some other 
countries，for use in sows and gilts (Kimman et al., 2009). However, 
Inactivated PRRSV vaccines have been proved to provide only partial 
protection upon challenge and therefore are considered to be ineffective 
or of limited efficacy at best, which signifies the importance of 
cell-mediated immunity in PRRSV prevention (Zuckermann et al., 2007). 
Modified-live (MLV) PRRSV vaccines are derived by gradual attenuation 
of virulent field isolates by serial passage on culturing cells. During 
homologous virulent strain challenge, MLV vaccines have shown better 
efficacy than inactivated PRRSV vaccines in reducing disease occurrence 
and severity (Labarque et al., 2003). However, MLV vaccines are only 
partially effective in providing protection against infections by 
heterologous field strains of PRRSV (Okuda et al., 2008). Moreover, there 
have been reports over the safety issues of the MLV vaccines, concerning 
the reversion of virulence during its multiplication in pigs (Nielsen et al., 
2001). 
Other experimental PRRSV vaccines include DNA vaccines, vectored 
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vaccines, and DIVA (differentiating infected from vaccinated animals) 
vaccines (Barfoed et al., 2004; Cruz et al., 2010; de Lima et al., 2008). But 
so far there hasn’t been a commercialized vaccine available from any of 
these candidates. Meanwhile, efforts have been made in utilization of 
immunoadjuvants for enhancing the efficacy of current PRRSV vaccines. 
These adjuvants include recombinant cytokines, synthesized reagents, 
and bacterial products. Among them, some interleukins (IL-2, IL-12 and 
Interferon-Alpha), poly I:C and CpG ODN show strong adjuvanticity in 
enhancing the CMI response to PRRSV vaccines, while the use of CpG 
ODN also enhance the PRRSV-specific antibody response after 
vaccination (Charerntantanakul, 2009). 
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Foot-and-mouth disease (FMD) is a high-ranked disease in the Office 
International des Epizooties (OIE) list of notifiable diseases, and is of 
great socio-economic consequence due to its potential of rapid 
international spread. Vaccination has proven to be a powerful strategy 
for disease control and eradication in FMD-endemic areas and during 
emergency outbreaks in areas normally free from the disease. However, 
in some cases vaccination against the FMD has failed to prevent the 
establishment and transmission of the disease, partly due to the failure 
in eliciting a fast and effective immune response by the vaccine used, 
which calls for a better FMD vaccine design strategy. 
Porcine reproductive and respiratory syndrome (PRRS) is a major swine 
disease that has spread worldwide and continues to cause great 
economic losses to the swine industry every year. Currently available 
vaccines against the disease mainly include killed virus (KV) vaccines and 
live attenuated vaccines. KV vaccines have been reported of limited 
efficacy, while live attenuated vaccines have shown better protection 
efficacy, especially against homologous infection. But the effectiveness 
of the live attenuated vaccines against heterologous infection is variable. 
Therefore, options as to the change of vaccination modes or the use of 
more powerful immunoadjuvants may help to enhance the efficacy of 
current PRRS live attenuated vaccines. 
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Due to the ever-increasing knowledge in the field of innate immunity, the 
past decade has witnessed a great number of studies in the development 
of novel immunoadjuvants, which are targeted at the direct activation of 
the innate immune system. Among those, CpG ODNs as one of the 
pathogen-associated molecular patterns (PAMP), have shown great 
potential in inducing strong Th1─biased immune response. In order to 
better the efficacy of current swine vaccines and develop novel adjuvants 
that are applicable to farm animals, the research in this study includes: 
1. The construction of plasmid containing multiple swine-specific CpG 
motifs and the study of its immunostimulatory effects in vitro; 
2. The study of the adjuvanticity of the CpG-enriched plasmid on a 
traditional foot-and-mouth disease killed vaccine that is currently 
used in China; 
3. The study of the adjuvanticity of the CpG-enriched plasmid on a 
porcine reproductive and respiratory syndrome live attenuated 
vaccine that is currently in use in China. 
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Adjuvants are administered with antigens to enhance the correspondent 
immune response stimulated by the latter. Since recombinant antigen 
proteins or synthetic peptides provide more biosafety than the crude 
inactivated micro-organism, while being less immunogenic, the specific 
and powerful adjuvants could play an important role in improving the 
efficacy of modern vaccines as the antigens become more purified 
(Aucouturier, Dupuis, and Ganne, 2001).  
Currently approved adjuvants include Aluminum Salts, Freund’s Adjuvant 
as well as certain oil and water emulsions (Reed et al., 2009). Oil-based 
adjuvants are nowadays in wide use for veterinary vaccines. However, 
they may cause local and general reactions, including fever, granuloma or 
abscesses, etc. Despite the impressive success of their adjuvanticity in 
generating immunity against viral and bacterial infections, there remains 
a need for the research and development of novel adjuvants that could 
enhance protective antibody responses, and those induce strong Th1 
immune response.  
Adjuvants are believed to take effects through a variety of mechanisms. 
Most of the traditional adjuvants serve as carriers or matrix for antigens 
(Petrovsky and Aguilar, 2004), while novel adjuvants are targeted at the 
direct activation of the innate immune system. During the past decade, 
many pattern recognition receptors (PRRs) and their corresponding 
signaling pathways in the innate immune system have been highlighted 
and the innate immune responses have proven to be capable of strongly 
influence the adaptive immune response (Schijns and Lavelle, 2011). 
Most members of the PRR families are potential targets for adjuvants 
derived from the PAMP molecules. Among them, CpG motif as a danger 
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signal could be recognized by TLR9 expressed on certain mammalian cells 
and cause direct B cell activation, implying its potential use as an 
immunoadjuvant (Klinman, 2004). Indeed, Incorporation of a higher 
number of CpG motifs into an FMD DNA vaccine candidate has proven to 
induce much stronger immune responses. During another investigation, 
treatment of the tight-skin mouse model of scleroderma with 
CpG-enriched plasmid has ameliorated the scleroderma-like syndrome in 
tight-skin mice (Shen et al., 2005; Zhang et al., 2005). In the current 
research, a swine-specific CpG motif enriched plasmid has been 
constructed and its immunostimulatory properties have been studied. 
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(1) The test of the immune stimulatory effect of pUC18-CpG in 
vitro—swine PBMCs lymphocyte transformation assay 
Unmethylated CpG motifs are more prevalent in the bacterial genome 
than in vertebrate genomic DNAs. Oligodeoxynucleotides (ODN) 
containing CpG motifs could activate host immune defense mechanisms, 
leading to innate immune responses including direct B cell activation and 
type I interferons expression (Krieg, 2006). During the early empirical 
structure–activity relationship studies, species-specific differences in the 
optimal CpG motif have been discovered, which for mice is GACGTT but 
GTCGTT for humans (Hartmann and Krieg, 2000; Krieg et al., 1995). 
Since the demand for safer and more powerful adjuvants in human and 
veterinary vaccinations is ever-increasing, as well as the application of 
animal models to human disease, it is worthwhile that CpG ODN be 
further investigated in veterinary species. During another study, optimal 
CpG motifs for veterinary and laboratory animals were screened via 
lymphocyte proliferation assay. And it has been shown that CpG motifs 
used for optimal immunostimulation are highly conserved among 
different veterinary species (Rankin et al., 2001).   
It has been reported that peripheral blood mononuclear cells (PBMCs) 
from pigs respond to ODNs containing specific CpG motifs by 
proliferating and secreting IL-6, IL-12 and TNF-α, and the optimal 
nucleotide sequence for swine PBMCs stimulation was found to be 
GTCGTT (Kamstrup, Verthelyi, and Klinman, 2001; Linghua et al., 2006). 
Hence，it would be of great practical importance to determine whether 
plasmid containing multiple CpG motifs is immunostimulatory in 
husbandry animals. With large scale fermentation and purification 
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process of the recombinant plasmid at a relatively lower cost (Sun et al., 
1994), CpG enriched plasmid may be of great value both as vaccine 
adjuvants (increasing both humoral as well as cell-mediated immune 
response elicited by protein, peptide-based antigens and DNA) and as 
immunoprotective agents.  
In the present study, we used a CpG motif enriched plasmid (pUC18-CpG) 
as an immune stimulator for swine PBMCs lymphocyte transformation 
assay. Our results showed that the Stimulation Index (SI) for the optimal 
dose of pUC18-CpG was more than 2.5 times higher than that of LPS, 
indicating that pUC18-CpG could be used as a potent immunopotentiator 
for enhancing humoral immune response.   
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(2) The test of the immune stimulatory effect of pUC18-CpG in 
vivo—enhancement on the efficacy of the traditional 
foot-and-mouth disease killed vaccine  
Foot-and-mouth disease is one of the notifiable diseases by the OIE and 
is of great socio-economic consequence because of its potential of rapid 
international spread. FMDV infection could cause high morbidity, with 
low to moderate mortality in most cases. Vaccination has proven to be a 
powerful strategy for disease control and eradication in FMD-endemic 
areas and in case of emergency outbreaks in areas normally free from 
the disease (Hutber et al., 2011).  
The currently in use FMD killed vaccine is manufactured by growing the 
live virulent strains of FMDV in BHK-21 cell lines under bio-secure 
conditions, inactivation by chemicals, and then formulated with 
oil-adjuvants (Doel, 2003). The synthetic peptide vaccine is also 
commercially available in China for the prevention and control of the 
disease. Other vaccine candidates under research include the live 
attenuated vaccines, empty capsid vaccines and live vector vaccines, etc. 
(Rodriguez and Grubman, 2009). 
Although the FMD killed vaccine has a number of positive characteristics, 
including the induction of immune protection upon challenge and thus 
the prevention and control of the disease, there are some major 
shortcomings of this vaccine and its production. The manufacturing 
process of FMD killed vaccine may risk the release of the live virus to the 
environment because of incomplete inactivation, causing biosafety 
issues. Also, FMD killed vaccine exhibits other disadvantages such as the 
need of adequate cold chain of formulated vaccines, necessity of 
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multiple vaccinations, short shelf life, etc. Moreover, the use of oil-based 
adjuvants may cause local and general reactions.  
On the other hand, synthetic peptide vaccines are designed to include 
both T and B cell antigenic epitopes optimized for both immunogenicity 
and antigenicity. But the efficacy of these vaccines is restricted by 
representing only a limited number of antigenic sites and/or T-cell 
epitopes of the virus. On these regards, a better FMD vaccine design 
strategy may provide more powerful FMD vaccines. 
Indeed, efforts as to the development of more efficacious adjuvants have 
been made during several previous studies. It has been reported that 
FMDV replication could be inhibited by type I interferons (Chinsangaram, 
Koster, and Grubman, 2001). Thus an Ad5 vector containing the porcine 
IFN-α gene expressed high levels of the biologically active interferon 
when infected the cells. And the pigs inoculated with a single dose of the 
recombinant vectored-vaccine were completely protected when 
challenged with FMDV (Chinsangaram et al., 2003).  
Poly(I:C) is a synthetic double-stranded polyribonucleotide, which could 
induce the expression of type I interferons. During another research, 
co-administration of a multi-epitope protein with poly(I:C) can greatly 
increase the neutralizing antibody response against FMDV in mice. And 
the poly(I:C) adjuvanted multi-epitope protein vaccine candidate 
completely protected pigs against virulent foot-and-mouth disease virus 
challenge (Cao et al., 2012; Cao et al., 2013).  
CpG ODNs are also strong inducers of type I IFNs. In a previous study, 
treatment of mice with CpG ODN alone significantly reduced viremia, the 
severity of disease and the death rate during the challenge with 
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foot-and-mouth disease virus (FMDV) (Kamstrup, Frimann, and Barfoed, 
2006).  
In our in vivo adjuvanticity test, pUC18-CpG was employed as vaccine 
adjuvant and co-administered with a commercial FMD killed vaccine. On 
day 14 after the initial vaccination, the average antibody titer in group D 
was 1.5 times higher than that in group B, implying that 
co-administration of pUC18-CpG may help bring forward the appearance 
of anti-structural protein antibodies. The early appearance of 
neutralizing antibodies is of great significance, especially when there is a 
need to perform enforced immunization in the neighboring zone during 
an outbreak of the disease (Patil et al., 2002). On day 28, the antibody 
titers of Groups C and D remained higher than that in Group B (p<0.05).  
To reduce the cost of CpG ODN production, which is normally via 
chemosynthesis, the CpG motifs were inserted into a plasmid vector, as 
described in the first paper. The adjuvant effect of the recombinant 
plasmid was then compared with that of the synthesized CpG ODN, 
which contains a phosphorothioate backbone. Both forms of CpG ODN 
were found to enhance the humoral immune response when 
co-administered with the traditional FMD killed vaccine in a previous 
animal experiment，generating higher antibody levels than that of the 
vaccine alone.  
During the initial vaccination period in the current study, there were 
significant differences (P < 0.05) in the antibody levels between the 
group vaccinated with the traditional oil-adjuvant FMD killed vaccine 
(group B) and the groups vaccinated with pUC18-CpG-adjuvant vaccine 
(groups C and D), with the antibody levels in the latter groups being 
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much higher. Since killed vaccines mainly trigger humoral immune 
responses, the levels of antibodies could be a useful indicator to evaluate 
the effectiveness of the vaccine used.  
After the booster vaccination, the average antibody titers in all 
vaccinated groups reached nearly the same high level and gradually 
declined to below 6 at the end of the experiment. The adjuvant effect of 
pUC18-CpG during this period was not as obvious as that observed 
during the initial vaccination period, partly because of the immune 
regulatory effects of the host immune system(Lim et al., 2005). 
According to the Manual of Diagnostic Tests and Vaccines for Terrestrial 
Animals issued by OIE, a commercial FMD vaccine for pigs should have at 
least 3 PD50 per dose for routine prophylactic use. To further validate the 
immunostimulatory effects of pUC18-CpG, a potency test was carried out 
to compare the PD50 values obtained with the traditional vaccine and 
that obtained with the pUC18-CpG adjuvanted vaccine. In our study, the 
PD50 value of the pUC18-CpG adjuvanted vaccine (12.51) was almost 
twice that of the traditional oil-adjuvant vaccine (6.47). Thus it is feasible 
to use the pUC18-CpG as a potent adjuvant for the traditional FMD killed 
vaccine, in order to achieve better immune protection effects. 
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(3) The test of the immune stimulatory effect of pUC18-CpG in 
vivo—enhancement on the efficacy of the porcine reproductive 
and respiratory syndrome live attenuated vaccine  
Porcine reproductive and respiratory syndrome (PRRS) is a swine disease 
that first emerged in the United States during the 1980s and later in 
Europe in 1981 (Madsen et al., 1998). Nowadays it has spread worldwide 
and continues to cause great economic losses to the swine industry 
every year. Currently available vaccines against the disease mainly 
include killed virus (KV) vaccines and live attenuated vaccines 
(Zuckermann et al., 2007). 
KV vaccines have been reported of limited efficacy, even against 
homologous challenge. Live attenuated vaccines have shown better 
protection efficacy, especially against homologous infection, but their 
effectiveness against heterologous infection is variable (Kimman et al., 
2009). Other experimental PRRSV vaccines include DNA vaccines, 
vectored vaccines, and DIVA (differentiating infected from vaccinated 
animals) vaccines. But so far there hasn’t been a commercialized vaccine 
available from any of these candidates. 
Ever since 2006, the emergence of a highly pathologic porcine 
reproductive and respiratory syndrome (HP-PRRS) has cost great loss to 
China’s swine industry (Li et al., 2007). Although PRRSV killed virus (KV) 
vaccine can elicit rapid IgM and IgG production after immunization, 
neutralizing antibodies (NAs) are not detectable until 28 DPI (Diaz et al., 
2005). Therefore, the protection efficacy of PRRSV killed vaccine is quite 
limited. Moreover, the early emergence of non-neutralizing antibodies 
may facilitate the entrance of the viruses into targeted cells by means of 
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the ADE mechanism (Cancel-Tirado, Evans, and Yoon, 2004).  
Efforts have been made in utilization of immunoadjuvants for enhancing 
the efficacy of current PRRSV vaccines. These adjuvants include 
recombinant cytokines, synthesized reagents, and bacterial products. 
Among them, some interleukins (IL-2, IL-12 and Interferon-Alpha), poly 
I:C and CpG ODN show great adjuvanticity in enhancing CMI response to 
PRRSV vaccines, while the use of CpG ODN also enhances the 
PRRSV-specific antibody response after vaccination(Charerntantanakul, 
2009). 
In previous studies, CpG ODN has been employed to enhance both Th1 
and Th2 responses to the PRRSV KV vaccine, and was found to 
significantly increase both cell-mediated and humoral responses against 
PRRSV in pigs, as well as the protective efficacy in challenge models 
(Linghua, Xingshan, and Fengzhen, 2007; Linghua et al., 2006). During 
another research, plasmid containing swine-specific CpG motifs could 
also augment the immune responses of pigs immunized with the PRRSV 
KV vaccine (Quan et al., 2010).  
In the present study, a commercial PRRSV live attenuated vaccine was 
chosen, and conferred better protection when co-administered with the 
plasmid pUC18-CpG. During the animal experiments, co-administration 
of pUC18-CpG with the commercial PRRSV live attenuated vaccine 
helped to elicit a stronger humoral immune response. PRRSV-specific 
antibody titers in Group B remained higher than that from the other 
vaccinated groups during the test. Antibody titers from Groups A and C 
showed no significant difference during the process, while the 
immunization dose in Group C was only 1/10 of that in Group A, 
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indicating the antigen dose saving property of the novel adjuvant 
(Weeratna, Comanita, and Davis, 2003).  
CpG ODN has been reported to trigger direct activation of antigen 
presenting cells and B cells, and induce a Th1 dominant cytokine profile 
(Corral and Petray, 2000; Krieg et al., 1995). In the current study, 
cytokines as IL-6 and IFN-γ were assayed, respectively. Although IL-6 has 
been reported to inhibit the Th1 polarization (Diehl and Rincon, 2002), 
high levels of IL-6 found in Group B may help to overcome the 
suppression effect of regulatory T cells (Pasare and Medzhitov, 2003), 
allowing for a stronger humoral immune response, as indicated by the 
higher antibody titers observed in Group B. Higher IFN-γ levels in Group 
B on day 14 indicated that addition of pUC18-CpG to PRRSV live 
attenuated vaccine could enhance the immune response in a Th1-biased 
way.  
After challenge, animals in both Groups A and B showed mild clinical 
symptoms compared to that observed in Groups C, D and the control 
group. Although the humoral immune response elicited in both Group A 
and Group C were comparable (p<0.05), animals from Group C exhibited 
much severe clinical symptoms. This may due to the different cytokine 
profiles that each vaccine stimulated in terms of type and quantity. 
Cytokines other than IL-6 and IFN-γ remain to be further studied, 
especially about their influences on the cell-mediated immune response.  
Virus excretion could be detected on days 7 and 14 in all groups post 
challenge, while animals in Group B showed the lowest percentage in the 
detection rate. On day 21, no virus excretion was detected in either 
Group A or B, while one animal from Group A died of PRRS on day 19 
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after challenge. Throughout the experiment, animals in Group B (full 
dose vaccine plus pUC18-CpG) showed the mildest clinical symptoms and 
full protection against challenge. In the meantime, viraemia could be 
detected in all groups on days 7 and 14. Animals in Group B showed the 
lowest detection rate, which is in accordance with the case of virus 
excretion. On day 21, animals in Group A and B showed no viraemia. 
Based on the above results, it is possible that the pUC18-CpG could be 
used as a potent adjuvant for the PRRSV live attenuated vaccine.   
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FIRST 
pUC18-CpG containing 20 copies of CpG ODN 2006 was achieved through 
tandem insertion of 5-copy CpG ODN 2006 into the multiple cloning sites 
of the pUC18 plasmid vector. 
PRIMERA 
El pUC18-CpG que contiene 20 copias de CpG ODN 2006 se logró a través 
de la inserción en tándem de 5-copia CpG ODN 2006 en los múltiples 
sitios de clonación del vector-plásmido pUC18. 
SECOND 
pUC18-CpG stimulated swine PBMCs proliferation was measured by the 
MTT colorimetric assay at different doses. Compared to the LPS positive 
control, pUC18-CpG showed higher SI, implying the potential use as a 
potent vaccine adjuvant.  
SEGUNDA 
Estudios de transformación de linfocitos se realizaron para valorar el 
efecto inmune del plásmido a diferentes dosis, utilizando el método del 
MTT. El pUC18-CpG demostró mayor índice de estimulación que el 
control positivo de LPS en todas las dosis estudiadas, lo que implica su 
potencial uso como un adyuvante potente. 
THIRD 
When co-administered with a traditional oil-adjuvant FMD killed vaccine 
FMDV OS/99，pUC18-CpG helped to elicit an early immune response, and 
enhance the anti-FMDV structural protein antibody titers by more than 
1.5 times higher during the first vaccination.  
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TERCERA 
Cuando se co-administra una vacuna inactivada de FA (OS/99) con el 
pUC18-CpG，se genera una respuesta inmune más temprana, mejorando 
los títulos de los anticuerpos, frente a la proteína estructural del VFA, 
más de 1,5 veces que el control durante la primera vacunación. 
FOURTH 
During the potency test, co-administration of pUC18-CpG with the FMD 
killed vaccine FMDV OS/99 (Serotype O, registered by the 
XinjiangTiankang Animal Science Bio-Technology Co., Ltd.) was shown to 
greatly enhance the potency of the mentioned vaccine (PD50 values: 
12.51, 6.47).   
CUARTA 
Durante la prueba de potencia, se mostró que la co-administración del 
pUC18-CpG con la vacuna inactivada del VFA (OS/99) mejoraba la 
potencia de esta última (PD50: 12.51, 6.47). 
FIFTH 
Co-administration of pUC18-CpG with a commercial PRRSV live 
attenuated vaccine JXA1-R helped to elicit a stronger humoral immune 
response. On day 21 post-vaccination, the PRRSV-specific antibody titers 
in the pUC18-CpG adjuvanted full-dose vaccine group was about 1.4 
times higher in comparison with the control group. 
QUINTA 
La co-administración del pUC18-CpG con una vacuna viva atenuada 
contra el síndrome reproductivo y respiratorio porcino (vacuna JXA1-R) 
ayudó a inducir una respuesta inmune humoral mayor que con solo la 
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vacuna. En el día 21 después de la vacunación, los títulos de anticuerpos 
específicos frente al virus de PRRS, en el grupo de animales vacunados 
con la dosis completa y con el adyuvante pUC18-CpG, fue alrededor de 
1.4 veces mayor que la del grupo control. 
SIXTH 
Co-administration of pUC18-CpG with the commercial PRRS live 
attenuated vaccine JXA1-R resulted in a Th1-type biased immune 
response. 14 days after the vaccination, the IFN-gamma levels in the 
pUC18-CpG adjuvanted full-dose vaccine group was almost 1.4 times 
higher in comparison with the control group.  
SEXTA 
La co-administración de pUC18-CpG con la vacuna viva atenuada del 
PRRS (JXA1-R) dio lugar a un tipo de respuesta inmune Th1. 14 días 
después de la vacunación, los niveles de IFN-gamma en el grupo 
vacunado con la dosis completa y el adyuvante pUC18-CpG fue 1,4 veces 
mayor que la del grupo control.  
SEVENTH 
Co-administration of pUC18-CpG with the commercial PRRS live 
attenuated vaccine could ameliorate the clinical symptoms and confer 
higher protection rate during challenge by the virulent PRRS virus JXA1. 
SÉPTIMA 
La co-administración de pUC18-CpG con la vacuna viva atenuada del 
PRRS podría conferir síntomas clínicos menos severos y una mayor tasa 
de protección durante el desafío por el virus PRRS virulento (JXA1). 
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EIGHTH 
The pUC18-CpG is proven to be a potent immunoadjuvant for the 
traditional FMD killed vaccine and the commercial PRRS live attenuated 
vaccine used in this study.  
OCTAVA  
El pUC18-CpG ha demostrado ser un potente inmunoadyuvante para la 
vacuna inactivada del virus de la fiebre aftosa y la vacuna viva atenuada 
de PRRS utilizadas en este estudio. 
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